![Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase | British Journal of Cancer Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2015.8/MediaObjects/41416_2015_Article_BFbjc20158_Fig1_HTML.jpg)
Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase | British Journal of Cancer
![Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. | Semantic Scholar Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4244574818b6181db84800ea19173a80fa71094b/2-TableII-1.png)
Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. | Semantic Scholar
![Electrochemical immunosensor for the breast cancer marker CA 15–3 based on the catalytic activity of a CuS/reduced graphene oxide nanocomposite towards the electrooxidation of catechol | SpringerLink Electrochemical immunosensor for the breast cancer marker CA 15–3 based on the catalytic activity of a CuS/reduced graphene oxide nanocomposite towards the electrooxidation of catechol | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00604-017-2532-5/MediaObjects/604_2017_2532_Figa_HTML.gif)
Electrochemical immunosensor for the breast cancer marker CA 15–3 based on the catalytic activity of a CuS/reduced graphene oxide nanocomposite towards the electrooxidation of catechol | SpringerLink
![Table 1 from Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar Table 1 from Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bf27a8f33dc1177ab0c7cf3c2adec21f5727b20d/3-Table1-1.png)
Table 1 from Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar
![Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients - ScienceDirect Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0009898115003265-t1.jpg)